Skip to main content

New Steroid Rules in Lupus? Let’s Talk. Dr. Michelle Petri breaks down the latest strategies to minimize steroid expos

Social Author Name
Dr. John Cush
Tweet Content
New Steroid Rules in Lupus? Let’s Talk. Dr. Michelle Petri breaks down the latest strategies to minimize steroid exposure while managing disease activity in lupus patients. 💡 Smarter steroid use = better outcomes. 👉 Watch now on RheumNow: https://t.co/vbjrXAlixz #Lupus https://t.co/04CjTkCqMJ

Telitacicept, recombinant fusion protein targeting BLyS & APRIL, studied in 41 Chinese SLE pts (added to standard Rx

Social Author Name
Dr. John Cush
Tweet Content
Telitacicept, recombinant fusion protein targeting BLyS & APRIL, studied in 41 Chinese SLE pts (added to standard Rx) showed mean improvements in SLEDAI-2K (10.0 to 6.25 @12 wks & 4.2 @24 wks;p<.001), daily prednisone (21 mg to 9.8mg) & proteinuria (2.8 gr to 1.3 gr/day) https://t.co/KHMWPeq79x
Comparing EULAR (2025) and ACR (2020) Guidelines on Safety of Lupus Medications in Pregnancy
Attendees at the 2025 RheumaPreg meeting were excited to discuss the newly released EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation. Table 1 summarizes the major recommendations from EULAR (2025) and the American College of Rheumatology (2020) reproductive guidelines for commonly used medications in SLE. It should be noted that these two sets of guidelines largely align, however, the updated EULAR guidelines have included some additional medications incorporating data from the last five years.

Metanalysis of ANCA-associated vasculitis with interstitial lung disease (8 studies, 654 pts shows the following signifi

Social Author Name
Dr. John Cush
Tweet Content
Metanalysis of ANCA-associated vasculitis with interstitial lung disease (8 studies, 654 pts shows the following significan mortality risk factors: age (HR 1.06), ever smoker (HR 1.61), UIP pattern (HR 2.07), acute exacerbation (HR 2.73) & microscopic polyangiitis (HR 4.03). https://t.co/Rf6c2gidpK

Cutaneous SLE

What labs do you order in discoid or SCLE patients?

Choices

T/F: Pathology can diagnose lupus with close to 100% accuracy

Choices

What is the most appropriate topical steroid for active discoid lupus on the face?

Choices

T/F: Drug-induced lupus can be distinguished from non drug-induced lupus.

Choices

In your patients, who usually diagnoses cutaneous lupus?

Choices

T/F: Photosensitivity can be discerned by history.

Choices

In your patients who have only cutaneous lupus, how do you assess disease activity?

Choices

What is your best option of CLE, when you cannot use hydroxychloroquine?

Choices

Who manages your Cutaneous LE patients?

Choices

Which form of cutaneous lupus is hardest to manage?

Choices

I'm a...

Choices

Tuesday Night Rheumatology: 🔓 Lupus Unlocked: Cutaneous SLE Join us for a discussion of the diagnosis, management,

Social Author Name
Dr. John Cush
Tweet Content
Tuesday Night Rheumatology: 🔓 Lupus Unlocked: Cutaneous SLE Join us for a discussion of the diagnosis, management, and latest insights into cutaneous manifestations of SLE. Featuring: Dr. Victoria P. Werth Dr. Matilda Nicholas Dr. Anthony Fernandez Dr. Christopher Richardson https://t.co/UNazbo9TuZ

Retrospective study of 131 childhoold SLE pts found lymphopenia (in 53%) significantly correlated w/ higher anti-dsDNA

Social Author Name
Dr. John Cush
Tweet Content
Retrospective study of 131 childhoold SLE pts found lymphopenia (in 53%) significantly correlated w/ higher anti-dsDNA and increased disease activity. (r = −0.63). Lymphopenia assoc w/ more nephritis (72%), HTN (24%), leukopenia (36%) & neuropsychiatric SLE https://t.co/ONUm84jThE

International Myositis Assessment and Clinical Studies Group (IMACS) reached a consensus on ‘anti-synthetase syndrome?

Social Author Name
Dr. John Cush
Tweet Content
International Myositis Assessment and Clinical Studies Group (IMACS) reached a consensus on ‘anti-synthetase syndrome’ as the preferred nomenclature and "ASyS" as the preferred abbreviation for the ‘anti-synthetase syndrome. https://t.co/TuTzVVZzZO https://t.co/EJkxX6aP56

Arterial or venous thrombotic events (AVTEs) are common w/ new forms of monogenic vasculitis (DADA2 & VEXAS), result

Social Author Name
Dr. John Cush
Tweet Content
Arterial or venous thrombotic events (AVTEs) are common w/ new forms of monogenic vasculitis (DADA2 & VEXAS), resulting from pathogenetic mechanisms of endothelial dysfunction, immune complex deposition and pro-inflammatory cytokines. Reviewed here. https://t.co/Nw9wNYssg3 https://t.co/5V0yrctaFI
Subscribe to
×